Merck KGaA said Friday that it has discontinued a Phase 2 trial for berzosertib in combination with topotecan in patients with relapsed, platinum-resistant small-cell lung cancer.
The German pharmaceuticals and chemicals company said that, following an interim analysis, the study was discontinued due to low probability of meeting the pre-defined objective of the trial.
"SCLC remains a difficult-to-treat disease, with minimal advances in the past 20 years," Merck said, adding that it will continue external studies exploring berzosertib in additional combinations and clinical settings.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.